DDTC-Cu(I) inhibits human osteosarcoma cells growth by repressing MET/PI3K/AKT signaling pathway

Abstract Osteosarcoma (OS) is a frequently occurring bone malignancy with increased metastatic properties, causing deaths in large numbers around the world. Disulfiram (DSF) is clinically utilized to treat alcohol dependency and has been indicated to bind Cu(I) in-vivo to form DDTC-Cu(I), which has...

Full description

Saved in:
Bibliographic Details
Main Authors: Ruhao Zhou, Lei Yan, Kun Zhang, Song Chen, Yang Yu, Xiaochun Wei, Yongchun Pan, Chaojian Xu, Xiaojuan Sun, Zhi Lv, Pengcui Li, Xiaochen Qiao, Yi Feng, Zhi Tian
Format: Article
Language:English
Published: Nature Portfolio 2025-07-01
Series:Scientific Reports
Subjects:
Online Access:https://doi.org/10.1038/s41598-025-06748-6
Tags: Add Tag
No Tags, Be the first to tag this record!
_version_ 1849334764528467968
author Ruhao Zhou
Lei Yan
Kun Zhang
Song Chen
Yang Yu
Xiaochun Wei
Yongchun Pan
Chaojian Xu
Xiaojuan Sun
Zhi Lv
Pengcui Li
Xiaochen Qiao
Yi Feng
Zhi Tian
author_facet Ruhao Zhou
Lei Yan
Kun Zhang
Song Chen
Yang Yu
Xiaochun Wei
Yongchun Pan
Chaojian Xu
Xiaojuan Sun
Zhi Lv
Pengcui Li
Xiaochen Qiao
Yi Feng
Zhi Tian
author_sort Ruhao Zhou
collection DOAJ
description Abstract Osteosarcoma (OS) is a frequently occurring bone malignancy with increased metastatic properties, causing deaths in large numbers around the world. Disulfiram (DSF) is clinically utilized to treat alcohol dependency and has been indicated to bind Cu(I) in-vivo to form DDTC-Cu(I), which has been confirmed for its antitumor effects. This investigation aimed to elucidate the efficacy of DDTC-Cu(I) on OS cell apoptosis, migration, growth, invasion, and underlying mechanisms. The in-vitro investigations were performed on U2OS, SaOS2, and MG-63 OS cell lines and included CCK-8, colony formation, RTCA, transwell invasion, flow cytometry, wound healing, and RNA seq assays. DDTC-Cu(I) was inoculated dose-dependent, increased apoptosis, and suppressed cells’ ability to proliferate, migrate, and invade via the MET and PI3K/AKT signaling pathways. Additionally, MET’s overexpression partially reversed the anti-OS and PI3K/AKT signaling pathways suppression effect of DDTC-Cu(I). Furthermore, the SaOS2 xenograft mice model was utilized to confirm the in-vivo anti-OS efficacy of DDTC-Cu(I) by MET protein inhibition. The histological research revealed that DDTC-Cu(I) had no adverse influence on the liver, heart, lungs, and kidneys. Overall, the data of this investigation suggested that DDTC-Cu(I) could serve as an efficient agent against OS development.
format Article
id doaj-art-636e2c8e8d5148c395ff20c439558aa6
institution Kabale University
issn 2045-2322
language English
publishDate 2025-07-01
publisher Nature Portfolio
record_format Article
series Scientific Reports
spelling doaj-art-636e2c8e8d5148c395ff20c439558aa62025-08-20T03:45:28ZengNature PortfolioScientific Reports2045-23222025-07-0115111210.1038/s41598-025-06748-6DDTC-Cu(I) inhibits human osteosarcoma cells growth by repressing MET/PI3K/AKT signaling pathwayRuhao Zhou0Lei Yan1Kun Zhang2Song Chen3Yang Yu4Xiaochun Wei5Yongchun Pan6Chaojian Xu7Xiaojuan Sun8Zhi Lv9Pengcui Li10Xiaochen Qiao11Yi Feng12Zhi Tian13Second Clinical Medical College, Shanxi Medical UniversitySecond Clinical Medical College, Shanxi Medical UniversitySecond Clinical Medical College, Shanxi Medical UniversitySecond Clinical Medical College, Shanxi Medical UniversitySecond Clinical Medical College, Shanxi Medical UniversitySecond Clinical Medical College, Shanxi Medical UniversityDepartment of Orthopedics, The Third People’s Hospital of Datong CitySecond Clinical Medical College, Shanxi Medical UniversitySecond Clinical Medical College, Shanxi Medical UniversitySecond Clinical Medical College, Shanxi Medical UniversitySecond Clinical Medical College, Shanxi Medical UniversitySecond Clinical Medical College, Shanxi Medical UniversitySecond Clinical Medical College, Shanxi Medical UniversitySecond Clinical Medical College, Shanxi Medical UniversityAbstract Osteosarcoma (OS) is a frequently occurring bone malignancy with increased metastatic properties, causing deaths in large numbers around the world. Disulfiram (DSF) is clinically utilized to treat alcohol dependency and has been indicated to bind Cu(I) in-vivo to form DDTC-Cu(I), which has been confirmed for its antitumor effects. This investigation aimed to elucidate the efficacy of DDTC-Cu(I) on OS cell apoptosis, migration, growth, invasion, and underlying mechanisms. The in-vitro investigations were performed on U2OS, SaOS2, and MG-63 OS cell lines and included CCK-8, colony formation, RTCA, transwell invasion, flow cytometry, wound healing, and RNA seq assays. DDTC-Cu(I) was inoculated dose-dependent, increased apoptosis, and suppressed cells’ ability to proliferate, migrate, and invade via the MET and PI3K/AKT signaling pathways. Additionally, MET’s overexpression partially reversed the anti-OS and PI3K/AKT signaling pathways suppression effect of DDTC-Cu(I). Furthermore, the SaOS2 xenograft mice model was utilized to confirm the in-vivo anti-OS efficacy of DDTC-Cu(I) by MET protein inhibition. The histological research revealed that DDTC-Cu(I) had no adverse influence on the liver, heart, lungs, and kidneys. Overall, the data of this investigation suggested that DDTC-Cu(I) could serve as an efficient agent against OS development.https://doi.org/10.1038/s41598-025-06748-6DisulfiramDDTC-Cu(I)OsteosarcomaRNA seqMET/PI3K/Akt signaling pathway
spellingShingle Ruhao Zhou
Lei Yan
Kun Zhang
Song Chen
Yang Yu
Xiaochun Wei
Yongchun Pan
Chaojian Xu
Xiaojuan Sun
Zhi Lv
Pengcui Li
Xiaochen Qiao
Yi Feng
Zhi Tian
DDTC-Cu(I) inhibits human osteosarcoma cells growth by repressing MET/PI3K/AKT signaling pathway
Scientific Reports
Disulfiram
DDTC-Cu(I)
Osteosarcoma
RNA seq
MET/PI3K/Akt signaling pathway
title DDTC-Cu(I) inhibits human osteosarcoma cells growth by repressing MET/PI3K/AKT signaling pathway
title_full DDTC-Cu(I) inhibits human osteosarcoma cells growth by repressing MET/PI3K/AKT signaling pathway
title_fullStr DDTC-Cu(I) inhibits human osteosarcoma cells growth by repressing MET/PI3K/AKT signaling pathway
title_full_unstemmed DDTC-Cu(I) inhibits human osteosarcoma cells growth by repressing MET/PI3K/AKT signaling pathway
title_short DDTC-Cu(I) inhibits human osteosarcoma cells growth by repressing MET/PI3K/AKT signaling pathway
title_sort ddtc cu i inhibits human osteosarcoma cells growth by repressing met pi3k akt signaling pathway
topic Disulfiram
DDTC-Cu(I)
Osteosarcoma
RNA seq
MET/PI3K/Akt signaling pathway
url https://doi.org/10.1038/s41598-025-06748-6
work_keys_str_mv AT ruhaozhou ddtccuiinhibitshumanosteosarcomacellsgrowthbyrepressingmetpi3kaktsignalingpathway
AT leiyan ddtccuiinhibitshumanosteosarcomacellsgrowthbyrepressingmetpi3kaktsignalingpathway
AT kunzhang ddtccuiinhibitshumanosteosarcomacellsgrowthbyrepressingmetpi3kaktsignalingpathway
AT songchen ddtccuiinhibitshumanosteosarcomacellsgrowthbyrepressingmetpi3kaktsignalingpathway
AT yangyu ddtccuiinhibitshumanosteosarcomacellsgrowthbyrepressingmetpi3kaktsignalingpathway
AT xiaochunwei ddtccuiinhibitshumanosteosarcomacellsgrowthbyrepressingmetpi3kaktsignalingpathway
AT yongchunpan ddtccuiinhibitshumanosteosarcomacellsgrowthbyrepressingmetpi3kaktsignalingpathway
AT chaojianxu ddtccuiinhibitshumanosteosarcomacellsgrowthbyrepressingmetpi3kaktsignalingpathway
AT xiaojuansun ddtccuiinhibitshumanosteosarcomacellsgrowthbyrepressingmetpi3kaktsignalingpathway
AT zhilv ddtccuiinhibitshumanosteosarcomacellsgrowthbyrepressingmetpi3kaktsignalingpathway
AT pengcuili ddtccuiinhibitshumanosteosarcomacellsgrowthbyrepressingmetpi3kaktsignalingpathway
AT xiaochenqiao ddtccuiinhibitshumanosteosarcomacellsgrowthbyrepressingmetpi3kaktsignalingpathway
AT yifeng ddtccuiinhibitshumanosteosarcomacellsgrowthbyrepressingmetpi3kaktsignalingpathway
AT zhitian ddtccuiinhibitshumanosteosarcomacellsgrowthbyrepressingmetpi3kaktsignalingpathway